---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-029822"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2023-08-22T23:59:59+00:00"
generated_at: "2026-06-11T05:47:13.960847+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma raises $10M via private placement; appoints new director

## Summary
- Gross proceeds of ~$10M from sale of 3.24M shares at $1.94/share and 1.91M pre-funded warrants at $1.9399.
- Net proceeds of ~$9.55M; funds to be used for working capital and general corporate purposes.
- Pre-funded warrants exercisable at $0.0001/share, no expiration, with 19.99% blocker provision.
- Company to file resale registration statement within 30 days, seek effectiveness within 45 days.
- Yekaterina Chudnovsky appointed to board as independent director effective August 22, 2023.

## SEC filing metadata
- accession: 0001493152-23-029822
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2023-08-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315223029822/0001493152-23-029822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315223029822/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-029822
- JSON: https://secwatch.observer/filing/0001493152-23-029822.json
- Plain text: https://secwatch.observer/filing/0001493152-23-029822.txt

## Key facts
- Executive change
  Yekaterina Chudnovsky was appointed as Director at Immix Biopharma, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective August 22, 2023 and in connection with the closing of the Private Placement, the Board of Directors (the “Board”) of the Company appointed Yekaterina Chudnovsky as a member of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1873835/000149315223029822/0001493152-23-029822-index.htm
- Material Agreements
  Immix Biopharma, Inc. entered into Securities Purchase Agreement with a certain accredited investor valued at approximately $10 million (effective 2023-08-21).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a certain accredited investor
  - Value: approximately $10 million
  - Effective: 2023-08-21
  source text: On August 21, 2023, Immix Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with a certain accredited investor (the “Purchaser”), pursuant to which the Company agreed to sell and issue to the Purchaser in a private placement transaction (the “Private Placement”) (i) 3,241,076 shares (the “Shares”) of the Company’s common stock, par value $0.0001 (“Common Stock”), and (ii) pre-funded warrants to purchase 1,913,661 shares of Common Stock (the “Pre-Funded Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1873835/000149315223029822/0001493152-23-029822-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.